New Leaf Venture Partners

New Leaf Venture Partners (NLV Partners ) is a U.S. sector-specialist healthcare venture capital firm headquartered in New York City, New York with additional offices in Menlo Park, California, focused on healthcare-technology investments across biopharmaceuticals and therapeutics, healthcare information technology and digital health, medical devices, diagnostics and healthcare services. The firm was originally established in 2005 as a spin-out from The Sprout Group (the venture capital arm of Donaldson, Lufkin & Jenrette / Credit Suisse), and is led by Managing Directors and Partners including Vijay Lathi, Srinivas Akkaraju, Ron Hunt, Liam Ratcliffe, and Craig Slutzkin. New Leaf invests across early- to growth-stage healthcare companies, with typical initial check sizes in the USD 5 to 25 million range, targeting Series A through pre-IPO rounds. The firm has raised multiple institutional healthcare-focused funds (New Leaf Venture Partners I, II, III, IV, V) with aggregate AUM exceeding USD 2 billion. Notable portfolio companies include Iterion Therapeutics, Arcus Biosciences (NYSE: RCUS), Edgewise Therapeutics (NASDAQ: EWTX), Praxis Precision Medicines (NASDAQ: PRAX), Recurion Pharmaceuticals (NASDAQ: RXRX), Tizona Therapeutics, Impel NeuroPharma, Ra Pharmaceuticals (acquired by UCB), and numerous other biopharmaceutical and healthcare-technology companies.